the aid library

LIST OPTIONS

Filter

7647

Sort by:

Direction:

Download (280)

View PDF (375)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (120)

View PDF (181)

Preparedness for cyclones, tropical storms, tornadoes, floods and earthquakes during the COVID-19 pandemic

World Health Organisation (WHO) (2023) C_WHO

The WHO health advisory provides guidance to countries on adapting all existing preparedness and response plans and procedures for natural hazards such as cyclones, tropical storms, tornadoes, floods, earthquakes and potential outbreaks of other diseases to their existing COVID-19 strategic prepared... more

Download (114)

View PDF (160)

Risk communication and community engagement: a compendium of case studies in times of COVID-19

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This collection of case studies on risk communication and community engagement (‎RCCE)‎ from 18 different country/area level public health partners in the WHO European Region provides evidence of numerous results achieved and lessons learned since the start of the COVID-19 pandemic. RCCE has not... more

Download (156)

View PDF (231)

Tracking progress on food and agriculture-related SDG indicators 2021

Food and Agriculture Organization of the United Nations (2021) C2

Tracking progress on food and agriculture-related SDG indicators 2021 - Food and Agriculture Organization of the United Nations

Download (112)

View PDF (158)

FAQs on COVID-19 Vaccines and Vaccination Program

Ministry of Health& Family Welfare, Goverment of India (2021) CC

Download (124)

View PDF (174)

Statement of guidance and recommendations to African Union Member States on the epidemic modelling of the COVID-19 pandemic

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Many African countries were amongst the most rapid to respond to the emerging threat of COVID-19, implementing large-scale interventions at very early stages of their epidemic. As demonstrated in this document using very simple models, this rapid mobilization and timeliness of implementing control m... more

Download (101)

View PDF (129)

Social and Economic Impact of COVID-19

E. Levy Yeyati; F. Filippini The Independent Panel (2021) CC

Background paper 13 The Independent Panel for Pandemic Preparedness and Response May 2021

Download (245)

View PDF (189)

Disease Surveillance, Emergency Preparedness and Response in Eastern and Southern Africa

World Bank, et al. (2021) CC

A Situational Assessment and Five-YearAction Plan for the Africa CDC Strengthening Regional Public Health Institutions and Capacity for Surveillance and Response Program

Download (83)

View PDF (121)

Coadministration of seasonal inactivated influenza and COVID-19 vaccines

World Health Organization WHO (2021) CC

Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related to coadministration of Covid-19 and influenza vacc... more

Download (81)

View PDF (679)

Managing stress and anger — COVID-19

Hesperian (2020) CC

Being away from our regular routines and the people we love can be hard. Lost income, crowded living spaces, violence, fear, uncertainty, and living with depression or other mental health problems can make it even harder. We will be living with these difficulties for a long time as we adjust to COVI... more

Download (74)

View PDF (765)

Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Karagiannidis, C.; et al. (2020) C1

DOI:https://doi.org/10.1016/S2213-2600(20)30316-7 The Lancet Respiratory Medicine

Download (148)

View PDF (172)

Selecting digital contact tracing and quarantine tools for COVID-19 : guiding principles and considerations for a stepwise approach

World Health Organization WHO, Western Pacific Region (2020) CC

Contact tracing is a key component of the COVID-19 response, particularly as societies begin to lift non-pharmaceutical interventions. However, it is a time-consuming and resource-intensive effort that depends on a trained and motivated workforce. Emergent digital contact tracing and quarantine (‎... more

Download (95)

View PDF (137)

OSCE human dimension commitments and state responses to the COVID-19 pandemic

Organization for Security and Co-operation in Europe OSCE (2020) CC

The COVID-19 pandemic has been a formative experience for all humanity and a health emergency of global proportions, presenting a huge challenge to national leaders, health systems, and citizens. The findings of a new report by the OSCE Office for Democratic Institutions and Human Rights (ODIHR) sho... more

Download (143)

View PDF (192)

Survey Tool and Guidance: Rapid, simple, flexible behavioural insights on COVID-19

World Health Organization WHO (2020) C_WHO

This document provides guidance to Member States in the WHO European Region that wish to conduct behavioural insights studies related to COVID-19. Studies can be used to monitor public knowledge, risk perceptions, behaviours and trust with the overall aim to inform national COVID-19 outbreak respons... more

Download (120)

View PDF (147)

Targeting and prioritization of impoverished and food-insecure populations affected by COVID-19 | Safeguarding and scaling up assistance for people most at risk

WFP (2020) CC

The outbreak of COVID-19 comes with unpredictable primary and secondary impacts on vulnerable and food-insecure populations across the world. Mortality and morbidity appear to be most acute for elderly people, and those with underlying health conditions. At the same time, the widely anti... more

Download (113)

View PDF (152)

COVID-19 v4: operational support and logistics: disease commodity packages
recommended

World Health Organization WHO (2020) C_WHO

30 April 2020 | COVID-19: Essential health services

Download (130)

View PDF (165)

Information Package on male circumcision and HIV Prevention - Insert 1

World Health Organization (WHO); UNAIDS; Unicef; et al. World Health Organization (WHO); UNAIDS; Unicef; et al. (2020) C_WHO

Introduction Accessed 02.03.2020

Download (147)

View PDF (151)

COVID-19 Vaccination, Country Readiness and Delivery: Supply and Logistics Guidance
recommended

World Health Organization WHO; UNICEF (2020) C_WHO

Working Document Nov. 2020 The COVAX Supply and Logistics workstream lead by UNICEF, Gavi and WHO have released a working copy of the COVID-19 Vaccination, Country Readiness & Delivery: Supply and Logistics Guidance. Countries might find this Guide useful when developing and strengthening their sup... more

Download (154)

View PDF (736)

South Africa Demographic and Health Survey 2016

National Department of Health - NDoH, Statistics South Africa, South African Medical Research Council SAMRC, and ICF (2019) CC

Large File: 12 MB!

Download (397)

View PDF (365)

Root and tuber crops: Untapped potential for food and nutrition security and rural livelihood development in Myanmar. Results of a scoping study

Moe Aung FoodSTART+ (2018) C1

This scoping study done in Myanmar offers the chance for FoodSTART+ to explore prospects for future partnerships in another important country of the region. The study was done from October 2016 to February 2017 and included visits to selected major potato and cassava production areas to meet with re... more

COVID-19 v4: operational support and logistics: disease commodity packages recommended

COVID-19 Vaccination, Country Readiness and Delivery: Supply and Logistics Guidance recommended

COVID-19 v4: operational support and logistics: disease commodity packages
recommended

COVID-19 Vaccination, Country Readiness and Delivery: Supply and Logistics Guidance
recommended